Influence of gelatinase B polymorphic variants and its serum levels in atherosclerosis

Genetic Testing and Molecular Biomarkers

Volumn 16, Issue 8, 2012, Pages 850-854

  Spurthi, Kondapalli Mrudula ^a   Galimudi, Rajesh Kumar ^a   Srilatha, Gantala ^a   Sahu, Sanjib Kumar ^b   Nallari, Pratibha ^a   Hanumanth, Surekha Rani ^a  

^a OSMANIA UNIVERSITY   (India)

^b Durga Bai Deshmukh Hospital and Research Centre   (India)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE PREDISPOSITION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ATHEROSCLEROSIS; BASE SEQUENCE; CASE-CONTROL STUDIES; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84865688950     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2011.0299     Document Type: Article

References (23)

1. Abilleira S, Bevan S, Markus HS (2006) The role of genetic variants of matrix metalloproteinases in coronary and carotid atherosclerosis. J Med Genet 43:897-901.
2. Cho HJ, Chae IH, Park KW, et al. (2002) Functional polymorphism in the promoter region of the gelatinase B gene in relation to coronary artery disease and restenosis after percutaneous coronary intervention. J Hum Genet 47:88-91.
3. Ketelhuth DF, Bäck M (2011) The role of matrix metalloproteinases in atherothrombosis. Curr Atheroscler Rep 13:162-169.
4. Davies MJ (1996) Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 94:2013-2020.
5. Galis ZS, Sukhova GK, Lark MW, Libby P (1994) Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94:2493-2503.
6. Haberbosch W, Gardemann A (2005) Gelatinase B C (-1562) T polymorphism in relation to ischaemic heart disease. Scand J Clin Lab Invest 65:513-522.
7. Henney AM, Wakeley PR, Davies MJ, et al. (1991) Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci U S A 88:8154-8158.
8. Jefferis BJ, Whincup P, Welsh P, et al. (2010) Prospective study of matrix metalloproteinase-9 and risk of myocardial infarction and stroke in older men and women. Atherosclerosis 208:557-563.
9. Johnson JL, Sala-Newby GB, Ismail Y, et al. (2008) Low tissue inhibitor of metalloproteinases 3 and high matrix metalloproteinase 14 levels defines a subpopulation of highly invasive foam-cell macrophages. Arterioscler Thromb Vasc Biol 28:1647-1653.
10. Kalela A, Ponnio M, Koivu TA, et al. (2000) Association of serum sialic acid and MMP-9 with lipids and inflammatory markers. Eur J Clin Invest 30:99-104.
11. Kim JS, Park HY, Kwon JH et al. (2002) The roles of stromelysin-1 and the gelatinase B gene polymorphism in stable angina. Yonsei Med J 43:473-481.
12. Libby P (1995) Molecular bases of the acute coronary syndromes. Circulation 91:2844-2850.
13. Mahajan N, Malik N, Bahl Yashpaul Sharma A, Dhawan V (2009) Correlation among soluble markers and severity of disease in non-diabetic subjects with pre-mature coronary artery disease. Mol Cell Biochem 330:201-209.
14. Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215.
15. Morgan AR, Zhang B, Tapper W, et al. (2003) Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease. J Mol Med 81:321-326.
16. Newby AC (2005) Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 85:1-31.
17. Noji Y, Kajinami K, Kawashiri MA, et al. (2001) Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Clin Chem Lab Med 39:380-384.
18. Szymanowski A, Nijm J, Kristenson M, Jonasson L (2011) Elevated levels of circulating matrix metalloproteinase-9 are associated with a dysregulated cortisol rhythm-A case-control study of coronary artery disease. Psychoneuroendocrinology 36:139-143.
19. Tayebjee MH, Lip GY, Tan KT, et al. (2005) Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease. Am J Cardiol 96:339-345.
20. Wang J, Warzecha D, Wilcken D et al. (2001) Polymorphism in the gelatinase B gene and the severity of coronary arterial stenosis. Clin Sci 101:87-92.
21. Ye S (2006) Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. Cardiovasc Res 69:636-645.
22. Zhang B, Ye S, Herrmann SM, et al. (1999) Functional polymorphism in the regulatory region ofgelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 99:1788-1794.
23. Zhi H, Wang H, Ren L, et al. (2010) Functional polymorphisms of matrix metallopeptidase-9 and risk of coronary artery disease in a Chinese population. Mol Biol Rep 37:13-20.